Immediate release fentanyl in general practices: Mostly off-label prescribing

References

• Hider‐Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol. 2018;84(6):1324–1334.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Santucci C, Radrezza S, et al. Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990–2016. Eur J Pain. 2019;23(4):697–707.
   PubMed Web of Science ®Google Scholar
• Hastie BA, Gilson AM, Maurer MA, et al. An examination of global and regional opioid consumption trends 1980–2011. J Pain Palliat Care Pharmacother. 2014;28(3):259–275.
   PubMedGoogle Scholar
• Stanley TH. The fentanyl story. J Pain. 2014;15(12):1215–1226.
   PubMed Web of Science ®Google Scholar
• Mounteney J, Giraudon I, Denissov G, et al. Fentanyls: are we missing the signs? Highly potent and on the rise in Europe. Int J Drug Policy. 2015;26(7):626–631.
   PubMed Web of Science ®Google Scholar
• Webster LR, Slevin KA, Narayana A, et al. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med. 2013;14(9):1332–1345.
   PubMed Web of Science ®Google Scholar
• Kuip E, Zandvliet M, Mathijssen R, et al. Pharmacological and clinical aspects of immediate release fentanyl preparations: criteria for selection. Eur J Hosp Pharm. 2012;19(1):38–40.
   Google Scholar
• Burns SM, Cunningham CW, Mercer SL. DARK classics in chemical neuroscience: fentanyl. ACS Chem Neurosci. 2018;9(10):2428–2437.
   PubMed Web of Science ®Google Scholar
• Smith H. A comprehensive review of rapid-onset opioids for breakthrough pain. CNS Drugs. 2012;26(6):509–535.
   PubMed Web of Science ®Google Scholar
• Schifano F, Chiappini S, Corkery JM, et al. Assessing the 2004–2018 fentanyl misusing issues reported to an international range of adverse reporting systems. Front Pharmacol. 2019;10:46.
   PubMed Web of Science ®Google Scholar
• Han Y, Yan W, Zheng Y, et al. The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. Transl Psychiatry. 2019;9(1):1–9.
   PubMedGoogle Scholar
• González‐Bermejo D, Rayón‐Iglesias P, Rodríguez‐Pascual A, et al. Drug utilization study on immediate release fentanyl in Spain. Prevalence, incidence, and indication. Pharmacoepidemiol Drug Saf. 2021;30(3):371–378.
   PubMed Web of Science ®Google Scholar
• Gazarian M, Kelly M, McPhee JR, et al. Off‐label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544–548.
   PubMed Web of Science ®Google Scholar
• Blum RS. Legal considerations in off-label medication prescribing. Arch Intern Med. 2002;162(15):1777–1779.
   PubMedGoogle Scholar
• Eguale T, Buckeridge DL, Verma A, et al. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 2016;176(1):55–63.
   PubMed Web of Science ®Google Scholar
• Conte C, Rousseau V, Vert C, et al. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports. Fundam Clin Pharmacol. 2020;34(4):518–520.
   PubMed Web of Science ®Google Scholar
• Oshikoya KA, Wharton GT, Avant D, et al. Serious adverse events associated with off-label use of azithromycin or fentanyl in children in intensive care units: a retrospective chart review. Paediatr Drugs. 2019;21(1):47–58.
   PubMed Web of Science ®Google Scholar
• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287–333.
   PubMed Web of Science ®Google Scholar
• Chen JH, Humphreys K, Shah NH, et al. Distribution of opioids by different types of Medicare prescribers. JAMA Intern Med. 2016;176(2):259.
   PubMed Web of Science ®Google Scholar
• Clark LT, Watkins L, Piña IL, et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019;44(5):148–172.
   PubMedGoogle Scholar
• Nalven T, Spillane NS, Schick MR, et al. Diversity inclusion in United States opioid pharmacological treatment trials: a systematic review. Exp Clin Psychopharmacol. 2021;29(5):524–538.
   PubMed Web of Science ®Google Scholar
• Gijsen R, Poos MJ. Using registries in general practice to estimate countrywide morbidity in The Netherlands. Public Health. 2006;120(10):923–936.
   PubMed Web of Science ®Google Scholar
• Biermans M, Verheij R, De Bakker D, et al. Estimating morbidity ratesfrom electronic medical records in general practice. Methods Inf Med. 2008;47(02):98–106.
   PubMedGoogle Scholar
• Osborne V, Layton D, Fogg C, et al. Utilization of fentanyl buccal tablets in England: exploring off‐label use reported in a cohort study. Eur J Pain. 2014;18(4):506–512.
   PubMed Web of Science ®Google Scholar
• Fleischman W, Auth D, Shah ND, et al. Association of a risk evaluation and mitigation strategy program with transmucosal fentanyl prescribing. JAMA Netw Open. 2019;2(3):e191340-e.
   Web of Science ®Google Scholar
• Perri-Plandé J, Miremont-Salamé G, Micallef J, French Addictovigilance Network, et al. A 13-year national monitoring study to assess narcotic prescriptions and indications (2007–2019). Drug Saf. 2022;45(1):37–44.
   PubMed Web of Science ®Google Scholar
• Schug SA, Ting S. Fentanyl formulations in the management of pain: an update. Drugs. 2017;77(7):747–763.
   PubMed Web of Science ®Google Scholar
• Thigpen JC, Odle BL, Harirforoosh S. Opioids: a review of pharmacokinetics and pharmacodynamics in neonates, infants, and children. Eur J Drug Metab Pharmacokinet. 2019;44(5):591–609.
   PubMed Web of Science ®Google Scholar
• Maheshwari M, Sanwatsarkar S, Katakwar M. Pharmacology related to paediatric anaesthesia. Indian J Anaesth. 2019;63(9):698–706.
   PubMed Web of Science ®Google Scholar